Cancer treatment reviews最新文献

{"title":"Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis","authors":"Shunsuke Nakatani ,&nbsp;Takuya Hayashi ,&nbsp;Keiko Yamamoto ,&nbsp;Hideki Maeda","doi":"10.1016/j.ctrv.2025.102923","DOIUrl":"10.1016/j.ctrv.2025.102923","url":null,"abstract":"<div><h3>Aims</h3><div>The primary objective was to assess the impact of HER2 loss after neoadjuvant therapy on the long-term prognosis of patients with HER2-positive breast cancer.</div></div><div><h3>Methods</h3><div>We extracted relevant studies from PubMed and Cochrane Library and performed systematic review and <em>meta</em>-analysis. The key eligibility criteria for the studies were as follows: included HER2-positive early breast cancer cases undergoing neoadjuvant therapy, available data on HER2 status before and after neoadjuvant therapy, and reported recurrence-related outcomes (disease-free survival/invasive disease-free survival/relapse-free survival) or overall survival.</div></div><div><h3>Results</h3><div>Of 915 studies that were initially identified, 8 met the eligibility criteria and were included in the <em>meta</em>-analysis for the recurrence-related outcomes (1,917 patients with HER2 loss: 411 [21.4 %] or HER2 retained: 1,506 [78.6 %]); 4 of them reported data on overall survival (606 patients with HER2 loss: 243 [40.1 %] or HER2 retained: 363 [59.9 %]). The average follow-up duration, based on data from five out of eight studies that reported this information, was 51.6 months. HER2 loss was significantly associated with worse recurrence-related outcomes (hazards ratio [HR] 1.85, 95 % confidence interval [CI] 1.31–2.61, p = 0.0005) and worse overall survival (HR 2.37, 95 % CI 1.27–4.41, p = 0.0065). No heterogeneity or publication bias was observed in the <em>meta</em>-analysis.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that compared with patients with HER2 retained, those with HER2 loss had significantly higher risk of disease recurrence and worse prognosis. These findings implied the possible use of HER2 loss as a prognostic factor in patients with HER2-positive early breast cancer. Reassessment of HER2 status after neoadjuvant therapy could be valuable in predicting prognosis and may lead to reconsideration of the rational subsequent treatment.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102923"},"PeriodicalIF":9.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”","authors":"Marco Donatello Delcuratolo ,&nbsp;Veronica Crespi ,&nbsp;Giorgio Saba ,&nbsp;Andrea Mogavero ,&nbsp;Valerio Maria Napoli ,&nbsp;Edoardo Garbo ,&nbsp;Massimiliano Cani ,&nbsp;Antonio Ungaro ,&nbsp;Maria Lucia Reale ,&nbsp;Alessandra Merlini ,&nbsp;Enrica Capelletto ,&nbsp;Paolo Bironzo ,&nbsp;Mario Levis ,&nbsp;Umberto Ricardi ,&nbsp;Silvia Novello ,&nbsp;Francesco Passiglia","doi":"10.1016/j.ctrv.2025.102918","DOIUrl":"10.1016/j.ctrv.2025.102918","url":null,"abstract":"<div><div>Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients’ selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102918"},"PeriodicalIF":9.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis","authors":"Fausto Petrelli ,&nbsp;Valentina Riboldi ,&nbsp;Lorenza Bruschieri ,&nbsp;Antonella Villa ,&nbsp;Fulvia Milena Cribiu’ ,&nbsp;Karen Borgonovo ,&nbsp;Mara Ghilardi ,&nbsp;Antonio Ghidini ,&nbsp;Silvia Seghezzi ,&nbsp;Agostina De Stefani ,&nbsp;Francesca Trevisan","doi":"10.1016/j.ctrv.2025.102921","DOIUrl":"10.1016/j.ctrv.2025.102921","url":null,"abstract":"<div><h3>Introduction</h3><div>Locally advanced cervical carcinoma (LACC) remains a significant global health issue, particularly in low- and middle-income countries (LMICs), where disease burden is highest. While cisplatin-based chemoradiotherapy (CTRT) has long been the cornerstone of first-line treatment, its toxicities, including nephrotoxicity and hematologic adverse events, limit its use in certain patients. Advances in systemic therapies, including immune checkpoint inhibitors and induction chemotherapy, offer new avenues for improving outcomes. This study aimed to evaluate the efficacy of various first-line regimens for LACC through a systematic review and Bayesian network <em>meta</em>-analysis (NMA), focusing on overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Materials and Methods</h3><div>This analysis adhered to PRISMA guidelines and included Phase III randomized controlled trials (RCTs) evaluating first-line treatments for LACC. The primary outcome was OS, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs), while PFS was secondary. A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Statistical analysis used a Bayesian NMA framework, with treatments ranked by surface under the cumulative ranking curve (SUCRA).</div></div><div><h3>Results</h3><div>Pembrolizumab + CTRT improved OS (HR, 0.67; 95 % CI, 0.50–0.90), while induction chemotherapy with carboplatin/paclitaxel followed by CTRT showed significant benefit (HR, 0.60; 95 % CI, 0.40–0.90). RT + cisplatin and 5-fluorouracil (5-FU) also improved OS (HR, 0.66; 95 % CI, 0.44–0.99), ranking highest in SUCRA analysis (98 %).</div></div><div><h3>Conclusion</h3><div>Three promising strategies—pembrolizumab-based regimens, induction chemotherapy followed by CTRT, and RT + CDDP + 5-FU—offer substantial survival benefits, advancing treatment options for LACC.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102921"},"PeriodicalIF":9.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials","authors":"Elvina Almuradova ,&nbsp;Davide Izzo ,&nbsp;Sara Gandini ,&nbsp;Aurora Gaeta ,&nbsp;Edoardo Giordano ,&nbsp;Carmine Valenza ,&nbsp;Gabriele Antonarelli ,&nbsp;Dario Trapani ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.ctrv.2025.102906","DOIUrl":"10.1016/j.ctrv.2025.102906","url":null,"abstract":"<div><div>Dose optimization in Phase I oncology trials balances therapeutic efficacy and patient safety. Traditional dose-escalation methods, such as the 3 + 3 design, primarily focus on safety, often resulting in prolonged exposure to subtherapeutic or excessively toxic doses. Additionally, these methods may fail to account for modern therapies’ complex pharmacokinetics and pharmacodynamics, including targeted agents and immunotherapies.</div><div>Contemporary approaches address these gaps by incorporating biomarkers, pharmacokinetic profiling, and patient-reported outcomes to guide personalized dosing strategies. Such methods improve the precision of dose selection and promote individualized cancer care. This review underscores the importance of distinguishing between dose-finding and dose optimization, advocating for designs that integrate patient perspectives and pharmacologic insights from early-phase trials. Additionally, we highlight the challenges of traditional methodologies and the importance of simplifying complex designs without compromising their scientific rigor. By embracing innovative approaches and patient-centered metrics, Phase I trials can evolve beyond safety assessments to expedite the delivery of effective and tailored cancer therapies.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"136 ","pages":"Article 102906"},"PeriodicalIF":9.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis","authors":"Tarek Assi ,&nbsp;Tania Moussa ,&nbsp;Carine Ngo ,&nbsp;Matthieu Faron ,&nbsp;Benjamin Verret ,&nbsp;Antonin Lévy ,&nbsp;Charles Honoré ,&nbsp;Clémence Hénon ,&nbsp;Cécile Le Péchoux ,&nbsp;Rastilav Bahleda ,&nbsp;Julien Vibert ,&nbsp;Axel Le Cesne","doi":"10.1016/j.ctrv.2025.102904","DOIUrl":"10.1016/j.ctrv.2025.102904","url":null,"abstract":"<div><div>Tenosynovial giant cell tumor is a non-malignant primary locally aggressive articular disease that affects the synovium of joints, tendon sheaths, and bursae. It is characterized by a translocation t (1;2), leading to the overexpression of CSF1 in the tumor microenvironment. CSF1 induces the recruitment of non-malignant cells, mainly macrophages, followed by the differentiation and polarization of these cells into the M2 phenotype. Surgery, particularly total synovectomy, remains the cornerstone of TGCT management. However, recurrence rates vary, reaching 40 to 60% in diffuse disease, often resulting in progressive joint dysfunction, pain, and potential need for joint replacement or limb amputation. Systemic therapy is recommended in recurrent TGCT in patients not amenable to additional surgery. Targeting the CSF1/CSF1R axis has successfully improved tumor responses and enhanced symptomatic function. In this review, we aim to explore contemporary paradigms in inoperable TGCT patients, with a focus on the physiopathology, clinical efficacy, and safety of CSF1 or CSF1R inhibitors.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102904"},"PeriodicalIF":9.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck","authors":"Petr Szturz ,&nbsp;Thorsten Fuereder ,&nbsp;Ye Guo ,&nbsp;Lisa Licitra ,&nbsp;Ricard Mesia ,&nbsp;Philipp Ivanyi ,&nbsp;Agustin Falco ,&nbsp;Makoto Tahara ,&nbsp;Marie-Noelle Solbes ,&nbsp;Filippo Venturini ,&nbsp;Paolo Bossi","doi":"10.1016/j.ctrv.2025.102910","DOIUrl":"10.1016/j.ctrv.2025.102910","url":null,"abstract":"<div><div>Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional guidelines recommend first-line therapy with an immune checkpoint inhibitor (with or without chemotherapy) or a cetuximab-based regimen, by assessment of expression levels of the biomarker programmed cell death-ligand 1 (PD-L1). However, patient- and tumor-specific factors, including the patient’s age, comorbidities, performance status, and tumor burden, kinetics and spread also need to be considered to optimize treatment in the first line. Additionally, with increasing availability of newer therapies globally, it is crucial to customize the subsequent second- or later-line therapy based on patient characteristics, including the previous therapy received. This review highlights the factors that should be considered for treatment decision-making in patients with R/M SCCHN. It also summarizes the current evidence for clinical outcomes based on treatment sequencing and provides guidance on choosing an optimal treatment regimen for patients in the first-line treatment setting and beyond.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102910"},"PeriodicalIF":9.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review","authors":"Edoardogregorio Galli ,&nbsp;Giorgio Patelli ,&nbsp;Federica Villa ,&nbsp;Nicole Gri ,&nbsp;Chiara Mazzarelli ,&nbsp;Iacopo Mangoni ,&nbsp;Cristiano Sgrazzutti ,&nbsp;Silvia Ghezzi ,&nbsp;Andrea Sartore-Bianchi ,&nbsp;Luca Saverio Belli ,&nbsp;Luciano De Carlis ,&nbsp;Angelo Vanzulli ,&nbsp;Salvatore Siena ,&nbsp;Katia Bencardino","doi":"10.1016/j.ctrv.2025.102908","DOIUrl":"10.1016/j.ctrv.2025.102908","url":null,"abstract":"<div><h3>Background</h3><div>Relapse after radical treatment remains a major concern in hepatocellular carcinoma (HCC), affecting 50–75 % of early-stage cases within 5 years. Early recurrence prediction is a clinical unmet need. Circulating blood biomarkers could provide a minimally invasive approach to detect minimal residual disease (MRD) post-intervention. Although alpha-fetoprotein has been the primary biomarker in this setting, its MRD sensitivity is limited to 50–70 %. This systematic review aims to summarize available evidence regarding the clinical validity and potential utility of emerging circulating blood biomarkers for MRD detection in HCC patients.</div></div><div><h3>Methods</h3><div>We searched PubMed and Embase for peer-reviewed articles and abstracts published up to 2025, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> for ongoing trials on circulating blood biomarkers for MRD in HCC.</div></div><div><h3>Results</h3><div>A total of 91 studies (74 with results and 17 ongoing, out of 2,386) were retrieved. We evaluated various blood biomarkers, including circulating DNA (cDNA, N = 24), circulating tumor cells (CTCs, N = 20), circulating RNA (cRNA, N = 8), and other miscellaneous (N = 22) for MRD detection in HCC. These biomarkers demonstrated encouraging results, albeit with notable heterogeneity. In particular, circulating tumor DNA (ctDNA) and CTCs stand as the most robust novel approaches, with 50–80 % sensitivity and specificity up to 94 %. Nonetheless, none of the 17 ongoing studies involve biomarker-driven intervention to prove clinical utility.</div></div><div><h3>Conclusions</h3><div>Novel circulating blood biomarkers are mature for MRD detection in HCC. However, variability in methodologies and results highlights the need for further validation. We encourage the investigation of CTCs and/or ctDNA in interventional trials to assess clinical utility. This biomarker-driven approach may enhance adjuvant treatment effectiveness in MRD-positive cases while minimizing toxicity in MRD-negative patients.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102908"},"PeriodicalIF":9.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist","authors":"F. Spada ,&nbsp;R.E. Rossi ,&nbsp;R. Modica ,&nbsp;F. Gelsomino ,&nbsp;M. Rinzivillo ,&nbsp;M. Rubino ,&nbsp;E. Pisa ,&nbsp;A.La Salvia ,&nbsp;N. Fazio","doi":"10.1016/j.ctrv.2025.102907","DOIUrl":"10.1016/j.ctrv.2025.102907","url":null,"abstract":"<div><h3>Introduction and aims</h3><div>Functioning neuroendocrine tumors (f-NETs) represent a minority of all NETs, however their management is challenging due to the impact on patients’ survival and quality of life. In addition to f-NETs, paraneoplastic syndromes (PNS) are due to substances that are not related to the primary anatomical site, they can develop in different phases of NETs evolution, and might complicate the patient’s clinical course. Dedicated guidelines are still scanty. We aim to review available literature on f-NETs to propose a useful tool for clinicians in order to improve the diagnostic process and the management.</div></div><div><h3>Methods</h3><div>Narrative review focused on f-NETs.</div></div><div><h3>Results</h3><div>The most common f-NETs include insulinomas, gastrinomas and carcinoid syndrome (CS)- associated NETs. Symptoms related to hormone production may overlap with other common endocrine and gastrointestinal disorders, highlighting the pivotal role of multidisciplinary management. Somatostatin analogs (SSAs) represent the gold standard first-line treatment of most f-NETs, often followed by or combined with other treatments (surgery, liver-directed therapies, targeted therapies, peptide receptor radionuclide therapy). Paraneoplastic syndromes can develop in different phases of NET evolution and might complicate the patient’s clinical course and response to therapy.</div></div><div><h3>Conclusions</h3><div>The management of hormonal syndromes is challenging and must be based on the multidisciplinary approach. Herein, we pointed out the minimal requirements for a NET specialist in the diagnosis and treatment of f-NETs. Efforts should be made to improve the awareness of functioning forms, to understand their pathogenesis and to improve their management.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102907"},"PeriodicalIF":9.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?","authors":"Flora Nguyen Van Long ,&nbsp;Brigitte Poirier ,&nbsp;Christine Desbiens ,&nbsp;Marjorie Perron ,&nbsp;Claudie Paquet ,&nbsp;Cathie Ouellet ,&nbsp;Caroline Diorio ,&nbsp;Julie Lemieux ,&nbsp;Hermann Nabi","doi":"10.1016/j.ctrv.2025.102909","DOIUrl":"10.1016/j.ctrv.2025.102909","url":null,"abstract":"<div><div>Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors represent the most common types of early-stage breast cancer. However, their response to adjuvant systemic treatments varies widely due to tumor heterogeneity. Current decisions for adjuvant treatment rely heavily on clinical and pathological characteristics, which can sometimes lead to overtreatment. Accurately identifying patients who will benefit from adjuvant chemotherapy at an individual level remains a challenge. Multigene profiling assays are now widely used in clinics to better assess recurrence risk and chemotherapy response for HR+ disease. In this report, we examine the advantages and limitations of two widely used molecular profiling tests—Oncotype DX and Prosigna. Both Oncotype DX and Prosigna have been demonstrated to be effective prognostic tools in early breast cancer, with Oncotype DX also being validated as a predictive tool to guide chemotherapy decisions. We focus on studies that directly compare these molecular tests and discuss how their strengths can be leveraged to improve clinical decision-making for early-stage HR+ breast cancers. Finally, we highlight remaining knowledge gaps and propose directions for future research.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102909"},"PeriodicalIF":9.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment and stratification of cardiovascular disease risk in people diagnosed with breast cancer: A scoping review","authors":"Mi Hye Jeon ,&nbsp;Tracey DiSipio ,&nbsp;Louise Wilson ,&nbsp;Gail Garvey ,&nbsp;Abbey Diaz","doi":"10.1016/j.ctrv.2025.102903","DOIUrl":"10.1016/j.ctrv.2025.102903","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Breast cancer patients are at increased risk of cardiovascular disease, which often are associated with cardiotoxic breast cancer treatment or overlapping risk factors between the two diseases. Pre-treatment cardiovascular risk assessment can enable accurate risk stratification and prevention of cardiovascular disease. Several tools have been suggested, described or used in research to assess baseline (pre-treatment) risk to determine appropriate cardiovascular disease care before, during and after cancer treatment. This scoping review aims to identify and describe key features of baseline cardiovascular disease risk assessment tools for breast cancer patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;PubMed, Embase and Google Scholar were searched for articles published January 2013 – March 2024 to identify publications reporting cardiovascular disease risk assessment tools in breast cancer patients. Publications included research articles (observational and experimental studies) and position/policy, commentary and review papers. Eligibility was assessed and key data were extracted independently by two reviewers. Conflicts were discussed and resolved with the authorship team.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total 144 articles were identified. Of these, 57 reported original data for the development, validation or recommendations of cardiovascular disease risk assessment tools and 87 reported the use of such tools. From these articles, 13 tools were identified that assessed the risk of cardiovascular disease broadly (n = 3) or death due to cardiovascular disease (n = 1) or specifically of cardiotoxicity or heart failure (n = 8) or venous thromboembolism (n = 1) in people diagnosed with breast cancer. Fourteen tools assessed cardiovascular disease risk in people diagnosed with mixed cancer types, including breast cancer. The planned development of four tools and/or surveillance pathways were described in protocol papers. Among all these tools identified (n = 31), seven tools (among these, four tools assessed people diagnosed with breast cancer only) went through external validation and performed poorly or moderately in stratifying cancer patients effectively into risk categories. Risk factors included in the assessment tools were age, breast cancer treatment type and pre-existing cardiovascular disease. While clinical guidelines and recommendations about baseline cardiovascular disease risk assessment were identified, these were either for cancer patients broadly or for cancer treatment types, and not specifically for people diagnosed with breast cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Several tools to assess baseline cardiovascular disease in people diagnosed with breast cancer were identified but only seven tools had gone through a validation process, and none were found to be very effective in differentiating people by baseline cardiovascular disease risk. Further work is needed to optimise the effectivene","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102903"},"PeriodicalIF":9.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}